Here, we present a mechanism that, in synergism with the previously proposed (12), could explain the kinetics of the EL-dependent reduction of LDL cholesterol observed in FH patients treated with ANGPTL3 inhibitors (18). Here, ANGPTL3 is linked to familial hyperaldosteronism.